source
- Leo Pharma to acquire experimental rare-skin disease drug dersimelagon in up to $435 million dealLeo Pharma announced it will acquire the rights to dersimelagon, an experimental oral therapy currently under FDA review, in a transaction that could total up to $435 million in upfront and near‑te…
- Amylyx reports positive pivotal trial results for drug targeting post-bariatric hypoglycemiaAmylyx announced that its experimental therapy achieved statistically significant improvement in patients who experience severe hypoglycemia after bariatric surgery. The company said the pivotal t…